Category: Cerevance

  • After ph2 win, Cerevance preps pivotal trials of novel Parkinson’s drug

    Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson’s disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech said today that the orally-active GPR6 inverse agonist reduced the time people with Parkinson’s experienced so-called ‘off’ episodes, when symptoms of the illness re-emerge […]